Mostrar el registro sencillo del ítem

dc.contributor.authorCouch, Fergus J.es_ES
dc.contributor.authorSánchez-Pérez, María J.es_ES
dc.date.accessioned2017-02-14T10:50:57Z
dc.date.available2017-02-14T10:50:57Z
dc.date.issued2016
dc.identifier.citationCouch, F.J.; et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 7: 11375 (2016). [http://hdl.handle.net/10481/44831]es_ES
dc.identifier.issn2041-1723
dc.identifier.urihttp://hdl.handle.net/10481/44831
dc.description.abstractCommon variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P<5 × 10−8) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P<0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for ∼11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction.en_EN
dc.description.sponsorshipB.C.A.C. was funded through a European Community Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175; COGS); Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692); the National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), R01 grants (CA128978, CA176785, CA192393), and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative); the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, the Breast Cancer Res. Foundation, and the Ovarian Cancer Research Fund. CIMBA genotyping was supported by National Institutes of Health grant (CA128978); the Department of Defence (W81XWH-10-1-0341); and the Breast Cancer Res. Foundation. CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. This study made use of data generated by the Wellcome Trust Case Control consortium. Functional studies were supported by the Florida Breast Cancer Foundation. A full description of funding and acknowledgments is provided in Supplementary Note 1.en_EN
dc.language.isoengen_EN
dc.publisherNature Publishing Groupen_EN
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/223175en
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licenseen_EN
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/en_EN
dc.subjectBreast canceren_EN
dc.subjectGenomeen_EN
dc.subjectLocien_EN
dc.subjectGene expressionen_EN
dc.titleIdentification of four novel susceptibility loci for oestrogen receptor negative breast canceren_EN
dc.typeinfo:eu-repo/semantics/articleen_EN
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen_EN
dc.identifier.doi10.1038/ncomms11375


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Excepto si se señala otra cosa, la licencia del ítem se describe como Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License